Rituxan (rituximab) - Roche
Higher risk of Long COVID among patients with autoimmune rheumatic diseases and immunomodulatory therapy: a retrospective cohort analysis of national US data. (PubMed, Arthritis Rheumatol) - Oct 15, 2026 - "The higher risk of developing Long COVID among AIRD patients compared with those without AIRD underscores the need to identify potential risk factors for Long COVID in this population to minimize its long-term effects." 
Journal • Retrospective data • Genetic Disorders • Immunology • Infectious Disease • Novel Coronavirus Disease • Obesity • Pulmonary Disease • Respiratory Diseases • Rheumatology • Sjogren's Syndrome
http://www.ncbi.nlm.nih.gov/pubmed/42870675
 
; A Jerrod Anzalone; Holland Stevenson; Jasvinder A Singh; Kaleb Michaud; Lesley E Jackson; Londyn Robinson; Maria I Danila; Namrata Singh; Rena C Patel; Sandra E Safo; Zachary Butzin-Dozier
 
Oct 15, 2026
 
Prev Next